TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, announced that a poster featuring its lead therapeutic candidate, TTX-MC138, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on Oct. 23 in Madrid, Spain. The presentation will highlight the latest clinical update from the Phase 1a trial evaluating TTX-MC138 in patients with advanced solid tumors.
TTX-MC138 is an investigational therapeutic designed to target miR-10b, a microRNA associated with metastatic disease progression. The ESMO Congress is a major global oncology forum, and presenting updated Phase 1a data there underscores the potential of TTX-MC138 to address unmet needs in metastatic cancer treatment. The Phase 1a trial is assessing the safety, tolerability, and preliminary efficacy of TTX-MC138 in patients with advanced solid tumors, and the updated results could provide early signals of clinical activity.
For TransCode Therapeutics, the presentation represents a key milestone in the clinical development of its lead candidate. The company’s focus on miR-10b, a well-documented biomarker of metastasis, positions it in the emerging field of RNA-targeted cancer therapies. If the Phase 1a data are favorable, they could support further clinical development and potentially attract partnering interest. The full press release can be viewed at https://nnw.fm/sGqsS.
The announcement comes as investors and researchers increasingly focus on therapies that specifically target metastatic mechanisms. TransCode’s approach with TTX-MC138 aims to inhibit miR-10b, which is overexpressed in metastatic tumors, and the ESMO presentation may offer the first clinical insights into this strategy. The company also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. For the latest news and updates relating to RNAZ, the company’s newsroom is available at https://nnw.fm/RNAZ.
The ESMO Congress 2026, scheduled for Oct. 23 in Madrid, will bring together oncology professionals from around the world to discuss the latest advances in cancer treatment. TransCode’s poster presentation will be among the scientific sessions, and the updated Phase 1a data could be a focal point for those following RNA-based therapeutics. The company’s participation highlights its commitment to advancing novel treatments for high-risk cancers.
NetworkNewsWire, a specialized communications platform focused on financial news and content distribution, published the announcement. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which offers InvestorWire for wire solutions and editorial syndication to 5,000+ outlets, among other services. The full terms of use and disclaimers are available at https://www.NetworkNewsWire.com/Disclaimer.
